Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Objectives: Chronic Viral Hepatitis B & C
3. The Human Hepatitis Viruses
4. Chronic HBV: A Global Health Problem
5. Immigration & Global HBV: "An Asian Disease"
6. HBV Transmission
7. Markers of HBV Infection
8. Natural History of HBV Infection
9. Natural History of Chronic HBV (1)
10. Natural History of Chronic HBV (2)
11. Phases of Chronic HBV Infection
12. Goals of Antiviral Treatment
13. Who Should Be Treated?
14. Guidelines of Chronic HBV Treatment (AASLD)
15. HBV Genotype Impact on Disease Progression
16. Response to Antiviral Therapy for HBV
17. Initial Treatment Considerations
18. PegINF vs. Nucleos(t)ide Analogs
19. Virologic Response in HBeAg+ Chronic HBV
20. Response to Therapy in HBeAg+ Chronic HBV
21. Virologic Response in HBeAg- Chronic HBV
22. Response to Therapy in HBeAg- Chronic HBV
23. Antiviral Drug Resistance in HBV
24. Antiviral Treatment Failure in HBV
25. Strategies to Limit Resistance
26. Monitor Response to HBV Therapy
27. Screen for HBsAg
28. HBV Vaccination
29. Chronic Hepatitis C: A Global Health Problem
30. At Risk for HCV
31. Global Risk from Nosocomial HCV
32. Hepatitis C - Natural History
33. Progression of Fibrosis in HCV Infection
34. Markers of HCV Infection
35. Goals of HCV Therapy
36. Interferons
37. Ribavirins
38. SVR by HCV Genotype in Naive Patients
39. Factors Predicting a Sustained Viral Response
40. Antiviral Therapy of HCV- Special Populations
41. Complications in Combination Therapy for HCV
42. HCV RNA: Sites for Drug Inhibition
43. Chronic HCV Therapy Strategy
44. HCV Protease Inhibition NS3-4A Complex
45. Telaprevir + PegIFN-2a and RBV
46. HCV Therapy Near New Horizons
47. Summary: Chronic Hepatitis B & C

Topics Covered

• Diagnosis, Natural History and Therapy of Hepatitis B
• Diagnosis, Natural History and Therapy of Hepatitis C

Links

Series:

• Gastroenterology and Hepatology

Categories:

• Clinical Practice

Therapeutic Areas:

• Gastroenterology & Nephrology

Talk Citation

Publication History

• Published on January 5, 2011
• Archived on July 22, 2016

Financial Disclosures

• Prof. Mark Mailliard, Grant/Research Support (Principal Investigator): Gilead Sciences